Comparing Ultragenyx Pharmaceutical (NASDAQ:RARE) and Kamada (NASDAQ:KMDA)

Kamada (NASDAQ:KMDA) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation and risk.

Profitability

This table compares Kamada and Ultragenyx Pharmaceutical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kamada	12.67%	9.36%	6.53%
Ultragenyx Pharmaceutical	-71.78%	N/A	-39.70%

Valuation and Earnings

This table compares Kamada and Ultragenyx Pharmaceutical”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kamada	$180.46 million	2.56	$20.20 million	$0.43	18.70
Ultragenyx Pharmaceutical	$673.00 million	2.42	-$575.00 million	($5.19)	-3.08

Kamada has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for Kamada and Ultragenyx Pharmaceutical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kamada	0	0	4	0	3.00
Ultragenyx Pharmaceutical	1	11	9	1	2.45

Kamada presently has a consensus price target of $13.75, indicating a potential upside of 70.98%. Ultragenyx Pharmaceutical has a consensus price target of $29.79, indicating a potential upside of 86.15%. Given Ultragenyx Pharmaceutical’s higher probable upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Kamada.

Institutional & Insider Ownership

20.4% of Kamada shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 36.1% of Kamada shares are owned by company insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Kamada has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500.

Summary

Kamada beats Ultragenyx Pharmaceutical on 10 of the 15 factors compared between the two stocks.

About Kamada

Kamada Ltd. is an Israeli biopharmaceutical company that develops, manufactures and markets plasma-derived therapies and specialty pharmaceutical products. Founded in 1990, the company is headquartered in Rehovot, Israel. Its products include Glassia, an alpha-1 proteinase inhibitor used to treat people with alpha-1 antitrypsin deficiency, and immune globulin therapies for conditions including rabies exposure, cytomegalovirus infection and varicella-zoster exposure. Kamada serves markets in the United States and internationally, selling products directly and through commercial partners.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare genetic diseases. Founded in 2010 and headquartered in Novato, California, the company works on therapies for conditions with limited treatment options, including enzyme deficiencies and metabolic disorders. Its marketed products include Crysvita (burosumab), used to treat certain forms of X-linked hypophosphatemia and tumor-induced osteomalacia; Mepsevii (vestronidase alfa), for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), for long-chain fatty acid oxidation disorders.